Proqr Therapeutics N v (PRQR) - News Archive

ProQR Therapeutics Set to Engage Investors at Upcoming Conferences: Advancing RNA Editing Innovations ProQR Therapeutics N.V. (Nasdaq: PRQR), a leader in the development of innovative RNA therapies, has announced its pa...

In the ever-evolving landscape of biotechnology, adaptability and foresight are essential for success. ProQR Therapeutics NV (Nasdaq: PRQR), a pioneering company focused on revolutionary RNA therapies supported by its p...

Advancements in RNA Editing: ProQR s Strategic Positioning and Leadership Reinforcement ProQR Therapeutics NV. A Pioneering Force in Transformative RNA Technologies ProQR Therapeutics NV. (Nasdaq: PRQR), based in Leiden...

ProQR Therapeutics NV, a pioneering company in the field of RNA therapies, is poised to present vital preclinical data on its innovative Axiomer RNA editing technology platform at the upcoming 20th Annual Meeting of the...

ProQR Joins Cantor Global Healthcare Conference Amid Stable Market Performance LEIDEN, the Netherlands, 2024 ProQR Therapeutics N.V. a company at the forefront of RNA therapies, is set to present at the 2024 Cantor Glob...

ProQR Therapeutics Reports Promising Q2 2024 Results, Reinforces Commitment to Transformative RNA Therapies In an announcement made on August 8, 2024, ProQR Therapeutics NV, a Netherlands and Massachusetts-based biophar...

ProQR Therapeutics Advances RNA Editing Technology Platform with Promising Preclinical Data and Nominates New Board MemberProQR Therapeutics, a pioneering company in the field of transformative RNA therapies, announced...

ProQR Therapeutics NV Reports Strong First Quarter 2024 Results and Provides Business UpdateLEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2024 - ProQR Therapeutics NV (Nasdaq: PRQR), a pioneering company committed to...

ProQR Therapeutics recently unveiled promising preclinical proof of concept data for its innovative Axiomer RNA editing technology platform. The company s flagship pipeline program, AX -0810, which focuses on addressing...

ProQR Therapeutics, a leading pharmaceutical company specializing in RNA therapies, has recently made significant progress in its Axiomer RNA editing technology platform. The company has successfully defended its key pa...

ProQR Therapeutics NV, a leading company in the field of transformative RNA therapies, recently announced its plans to present new preclinical data on its proprietary Axiomer RNA editing technology platform at the Ameri...

ProQR s Axiomer IP Portfolio Successfully Defended Against OppositionLEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 - ProQR Therapeutics N.V. (Nasdaq: PRQR), a leading company specializing in RNA therapies, has...

ProQR Therapeutics NV, a dedicated company focusing on revolutionizing RNA therapies using its proprietary Axiomer RNA editing technology platform, recently presented significant advancements at the 5th International Co...